European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Rise 2% for Week

MT Newswires Live00:14

European equities traded in the US as American depositary receipts were down late Friday morning, falling 0.79% to 2,881.99 on the S&P Europe Select ADR Index, which was up 2% for the week.

From continental Europe, the gainers were led by biopharmaceutical firm DBV Technologies (DBVT) and pharmaceutical company Novo Nordisk (NVO), which advanced 12% and 4.8%, respectively. They were followed by petroleum refiner Equinor (EQNR) and biotech firm BioNTech (BNTX), which increased 2.4% and 2.2%, respectively.

The decliners from continental Europe were led by medical device maker EDAP TMS (EDAP) and pharmaceutical company Ascendis Pharma (ASND), which fell 7.1% and 3.3% respectively. They were followed by internet advertising firm Criteo (CRTO) and healthcare tech company Royal Philips (PHG), which were down 1.5% and 1.4% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Biodexa Pharmaceuticals (BDRX), which rose 1.7% and 1.4% respectively. They were followed by utilities company National Grid (NGG) and oil and gas company BP (BP), which were up 1% each.

The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and pharmaceutical company Silence Therapeutics (SLN), which shed 9.7% and 4.5% respectively. They were followed by mining company BHP Group (BHP) and educational publisher Pearson (PSO), which dropped 2.5% each.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment